Table 2 Medication and management of rheumatoid arthritis participants in a selected comprehensive specialized hospital, North West Ethiopia, 2024 (N = 393).
Medication | Percentage (%) |
|---|---|
Meloxicam, folic acid, MTX, prednisolone, indomethacin | 12 (3.1%) |
Meloxicam, ibuprofen | 82 (20.8%) |
Meloxicam, MTX, folic acid | 4 (1.02%) |
MTX, folic acid, indomethacin, meloxicam | 24 (6.12%) |
MTX, folic acid | 39 (9.9%) |
MTX, folic acid, indomethacin | 28 (7.12%) |
MTX, folic acid, meloxicam, indomethacin | 23 (5.85%) |
MTX, folic acid, meloxicam, prednisolone | 22 (5.58%) |
MTX, folic acid, indomethacin, prednisolone | 12 (3.1%) |
MTX, folic acid, prednisolone | 47 (11.95%) |
MTX, folic acid, indomethacin, prednisolone, meloxicam | 11 (2.79%) |
Meloxicam, folic acid, MTX, tramadol | 11 (2.79%) |
Meloxicam, diclofenac, chloroquine | 11 (2.79%) |
Indomethacin, prednisolone | 31 (7.89%) |
Meloxicam, folic acid, indomethacin | 24 (6.1%) |
Folic acid, MTX, prednisolone | 12 (3.1%) |
